March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Exosomes From Retinal Astroglial Cells (RACs) Suppressed New Vessel Formation In a Laser-induced CNV Model
Author Affiliations & Notes
  • Amir R. Hajrasouliha
    Ophthalmalogy & Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky
  • Guomin Jiang
    Ophthalmalogy & Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky
  • Huayi Lü
    Ophthalmalogy & Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky
  • Wei Wang
    Ophthalmalogy & Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky
  • Henry J. Kaplan
    Ophthalmalogy & Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky
  • Hui Shao
    Ophthalmalogy & Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky
  • Footnotes
    Commercial Relationships  Amir R. Hajrasouliha, None; Guomin Jiang, None; Huayi Lü, None; Wei Wang, None; Henry J. Kaplan, None; Hui Shao, None
  • Footnotes
    Support  Supported in part by NIH grants NEI EY12974 (HS), Research to Prevent Blindness (RPB) Lew R. Wasserman Merit Award (HS), and the Department's RPB Unrestricted Grant (HK).
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2016. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amir R. Hajrasouliha, Guomin Jiang, Huayi Lü, Wei Wang, Henry J. Kaplan, Hui Shao; Exosomes From Retinal Astroglial Cells (RACs) Suppressed New Vessel Formation In a Laser-induced CNV Model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2016.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Choriodal neovascularization (CNV) is a devastating complication of age-related macular degeneration (AMD), a leading cause of blindness in the developed world. In this study, we tested whether the exosomes released from normal tissue cells is an alternative and better therapy for CNV.

Methods: : CNV in C57BL/B6 (B6) mice was induced by 4 laser spots (50um diameter at 250mV, 0.5s energy) around the optic disc. Exosomes released from cultured murine retinal astroglial cells (RAC), RPE, fibroblasts or dendritic cells (DC) were isolated. Mice with CNV were injected periocularly (in sub-Tenon’s space) with PBS or derived exosomes daily starting on day 0. On day 7 mice were perfused with PBS containing 50 mg/ml fluorescein-labeled dextran (FITC-dextran). The incidence of active CNV was observed in vivo by fluorescence microscopy. The incidence and area of new vessel formation in the choroid was determined in choroid flat mounts using fluorescent microscopy. Macrophage infiltration into CNV lesions was evaluated by immunostaining with F4/80 Ab.

Results: : Exosomes were detected in the retina 15 min after peri-ocular injection. Active CNV was completely inhibited after treatment with RAC exosomes compared to 42% incidence in PBS-treated mice. On choroid flat mounts incidence of CNV was observed in 75% of control laser spots versus 40% in RAC-exosome treated group. In addition, RAC exosome-treated mice had 83% less area of new vessels in the choroid than those in PBS-treated mice. Macrophage infiltration was also significantly reduced in RAC exosome-treated group compared to control (27 ± 4 vs. 60 ± 13 macrophage per laser spot, respectively, P<0.05). Exosomes derived from RACs had the strongest treatment efficacy compared to RPE, fibroblast and DC derived exosomes.

Conclusions: : RAC exosomes contain anti-angiogenic molecules that can inhibit active CNV. Thus, RAC exosomes may represent a novel treatment for CNV in AMD.

Keywords: age-related macular degeneration • retinal glia • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×